Bluebird Bio

FDA grants priority review to ide-cel, keeping Bristol Myers on track to deliver Celgene payday
FDA grants priority review to ide-cel, keeping Bristol Myers on track to deliver Celgene payday
Fierce Biotech
Bristol-Myers Squibb
Celgene
Bluebird Bio
FDA
priority review
ide-cel
Flag link:
Bristol Myers resubmits cancer cell therapy, lifting investors' chance at payout
Bristol Myers resubmits cancer cell therapy, lifting investors' chance at payout
BioPharma Dive
Bristol-Myers Squibb
Bluebird Bio
FDA
ide-cel
cell therapy
Multiple Myeloma
Flag link:
New CRISPR, gene therapy results strengthen potential for treatment of blood diseases
New CRISPR, gene therapy results strengthen potential for treatment of blood diseases
BioPharma Dive
CRISPR
gene therapy
beta thalassemia
sickle cell disease
CRISPR Therapeutics
Vertex
Bluebird Bio
EHA
Flag link:
EHA 2020 – Bluebird’s sickle cell plan takes shape, with a stark reminder
EHA 2020 – Bluebird’s sickle cell plan takes shape, with a stark reminder
EP Vantage
Bluebird Bio
sickle cell disease
LentiGlobin
EHA
Flag link:
What Sanofi Might Buy With Its Regeneron Windfall
What Sanofi Might Buy With Its Regeneron Windfall
Barron's
Sanofi
Regeneron
M&A
gene therapy
Ultragenyx
Bluebird Bio
Flag link:
FDA Mishaps Have Investors Asking “What’s Going On With bluebird bio?”
FDA Mishaps Have Investors Asking “What’s Going On With bluebird bio?”
Motley Fool
Bluebird Bio
beta thalassemia
LentiGlobin
FDA
pandemic
clinical trials
Flag link:
Biotech companies raise cash as coronavirus updates lift stocks
Biotech companies raise cash as coronavirus updates lift stocks
BioPharma Dive
biotech
biotech stocks
COVID-19
Moderna Therapeutics
Bluebird Bio
Turning Point Therapeutics
Gossamer Bio
Krystal Biotech
Clovis Oncology
Gamida Cell
Bellerophon
Flag link:
Ahead of ASCO, Bristol Myers Squibb Announces Results for Three Clinical Trials
Ahead of ASCO, Bristol Myers Squibb Announces Results for Three Clinical Trials
BioSpace
Bristol-Myers Squibb
Opdivo
Yervoy
non-small cell lung cancer
ide-cel
Multiple Myeloma
Bluebird Bio
ASCO 2020
Flag link:
Bristol Myers Squibb Receives a 'Refuse to File' Letter for an Experimental Cancer Therapy on a Deadline
Bristol Myers Squibb Receives a 'Refuse to File' Letter for an Experimental Cancer Therapy on a Deadline
Motley Fool
Bristol-Myers Squibb
Bluebird Bio
refusal to file letter
FDA
ide-cel
Flag link:
Bristol Myers Squibb Offers bluebird bio a $200 Million Royalty Buyout
Bristol Myers Squibb Offers bluebird bio a $200 Million Royalty Buyout
Motley Fool
Bristol-Myers Squibb
Celgene
M&A
Bluebird Bio
Flag link:
Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T
Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T
Endpoints
Bristol-Meyers Squibb
CAR-T
Celgene
ide-cel
Bluebird Bio
liso-cel
ozanimod
Flag link:
Bluebird says gene therapy application delayed again, citing disagreement with FDA
Bluebird says gene therapy application delayed again, citing disagreement with FDA
BioPharma Dive
Bluebird Bio
LentiGlobin
FDA
Flag link:
Why AnaptysBio, bluebird bio, and Exelixis Shares Rebounded Last Friday
Why AnaptysBio, bluebird bio, and Exelixis Shares Rebounded Last Friday
Motley Fool
pharma stocks
AnaptysBio
Bluebird Bio
Exelixis
COVID-19
Flag link:
Why So Many Biotechs Are Scrambling to Develop a Drug for the Same Rare Disease
Why So Many Biotechs Are Scrambling to Develop a Drug for the Same Rare Disease
Motley Fool
beta thalassemia
rare disease
drug development
Acceleron
Bristol-Myers Squibb
Bluebird Bio
Sangamo Therapeutics
Vertex Pharmaceuticals
Editas Medicine
Syros Pharmaceuticals
Flag link:
bluebird bio Beats Its Q4 Revenue Target but Misses on EPS
bluebird bio Beats Its Q4 Revenue Target but Misses on EPS
Motley Fool
Bluebird Bio
earnings
Flag link:
CAR-T tackles multiple myeloma by using the target CD229 to kill cancer stem cells
CAR-T tackles multiple myeloma by using the target CD229 to kill cancer stem cells
Fierce Biotech
CAR-T
Multiple Myeloma
CD229
JNJ
Bluebird Bio
Flag link:
5 biopharmas to watch as the decade's last earnings kick off
5 biopharmas to watch as the decade's last earnings kick off
BioPharma Dive
earnings
Novartis
Biogen
Eli Lilly
Global Blood Therapeutics
Bluebird Bio
Flag link:
Who are the 10 Most Innovative Biopharma Companies?
Who are the 10 Most Innovative Biopharma Companies?
BioSpace
innovation
Regeneron
Verily
Illumina
Biogen
Bayer
Bluebird Bio
Novartis
GSK
Genentech
Amgen
Flag link:
LentiGlobin gene therapy for sickle cell on course for filing, says bluebird
LentiGlobin gene therapy for sickle cell on course for filing, says bluebird
Pharmaforum
LentiGlobin
Bluebird Bio
sickle cell disease
Flag link:
Myeloma cell therapies, now in pharma hands, move into spotlight
Myeloma cell therapies, now in pharma hands, move into spotlight
Biopharma Dive
ASH2019
cell therapies
Multiple Myeloma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
Flag link:

Pages